601 results on '"Witzens‐Harig, Mathias"'
Search Results
2. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
3. Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis
4. 1 Kardiologie und Angiologie Kardiologie Angiologie
5. 4 Gastroenterologie Gastroenterologie
6. 7 Nephrologie Nephrologie
7. 8 Wasser-, Elektrolyt- und Säure-Basen-Haushalt Wasser-, Elektrolyt- und Säure-Basen-Haushalt
8. 6 Endokrinologie und Stoffwechsel Endokrinologie
9. 13 Anhang
10. 10 Rheumatologie Rheumatologie
11. 3 Pneumologie Pneumologie
12. Vorwort
13. 2 Hämatologie Hämatologie
14. 9 Immunologie Immunologie
15. 12 Intensivtherapie Intensivtherapie
16. 5 Leber, Gallenblase, Pankreas Gallenblase Pankreas Leber
17. Sachverzeichnis
18. Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
19. Ibrutinib
20. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
21. Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection
22. Supplementary Table 1 from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
23. Data from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
24. Supplementary Table 2 from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
25. Supplementary Figures from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
26. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
27. Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation
28. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma
29. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
30. HCV load as a possible prognostic factor in patients with HCV-related DLBCL
31. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma
32. Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center Experience
33. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
34. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
35. Ibrutinib
36. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
37. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases
38. First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
39. The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas
40. Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
41. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma
42. In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study
43. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial
44. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells
45. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
46. Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection
47. Sarcoidosis and the occurrence of malignant diseases
48. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
49. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial
50. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.